Core Viewpoint - The company anticipates a significant increase in losses for the fiscal year 2025 compared to the previous year, with projected net losses ranging from 29.4 million to 44 million yuan [2][4]. Financial Performance Forecast - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses of 27.4 million to 41.99 million yuan compared to the previous year [2][4]. - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses of 10.06 million to 50.96 million yuan compared to the previous year [2][4]. Previous Year Performance - In 2024, the company reported a total profit of 4.1872 million yuan, with a net loss attributable to the parent company of -200.17 million yuan. The net profit excluding non-recurring gains and losses was -71.8371 million yuan [6]. Reasons for Performance Changes - The increase in losses is attributed to intensified industry competition and ongoing medical procurement policies, which have led to a decrease in revenue from self-produced diagnostic test products due to a VAT adjustment to 13% [7]. - The company has made efforts to reduce long-term accounts receivable, resulting in a decrease in the balance of such receivables [7]. - The company has recognized impairment provisions for various assets based on prudence principles, in accordance with accounting standards [7]. - There has been a reduction in government subsidies received during the reporting period [8]. - Despite a decrease in R&D spending, the company maintains a relatively high intensity of R&D investment, focusing on core product lines and enhancing overall solution capabilities [9].

Core Viewpoint - The company, Shuoshi Biotechnology (688399), has announced a forecast for a significant increase in losses for the year 2025, with expected net losses ranging from 29.4 million to 44 million yuan, compared to a loss of 200.17 thousand yuan in the previous year [4]. Financial Performance - The forecasted net profit attributable to the parent company for 2025 is expected to be a loss of 29.4 million to 44 million yuan, while the non-recurring net profit is projected to be a loss of 81.9 million to 123 million yuan, compared to a loss of 71.8 million yuan in the previous year [4]. - The company's price-to-book ratio (LF) is approximately 2.03 times, and the price-to-sales ratio (TTM) is about 17.79 times based on the latest closing price [4]. Business Operations - The company specializes in in vitro diagnostic reagents and related testing instruments [15]. - Despite stable development in its main business, the company has faced challenges due to intensified industry competition and ongoing medical procurement policies, leading to a decrease in revenue from self-produced testing reagents [15]. - The company has implemented cost reduction and efficiency enhancement measures, aiming to maintain a stable gross profit margin compared to the previous year [15]. - The company has focused on improving the collection of accounts receivable, resulting in a gradual decrease in long-aged accounts receivable balances [15]. - The company has reduced government subsidies received during the reporting period [15]. Research and Development - The company continues to prioritize research and development investments, maintaining a relatively high intensity of R&D spending despite a year-on-year decline [15]. - The company is focusing on refining its core product lines and enhancing its overall solution capabilities in product development [15].

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), is expected to report a significant increase in losses for the fiscal year 2025, with projected net losses ranging from 29.4 million to 44 million yuan, compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses by 27.4 million to 41.9 million yuan compared to the previous year [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses by 10.1 million to 50.9 million yuan compared to the previous year [1] Business Operations - The company's main business has shown stable development; however, it has been impacted by intensified industry competition and ongoing medical procurement reforms, leading to a decrease in revenue from self-produced diagnostic reagents due to a VAT adjustment to 13% [1] - The company is actively implementing cost reduction and efficiency enhancement measures, aiming to maintain a stable overall gross profit margin compared to the previous year [1] Accounts Receivable Management - The company has intensified efforts to collect accounts receivable, resulting in a gradual decrease in the balance of long-aged accounts receivable [1] - There has been a reduction in the reversal of impairment provisions for receivables compared to the previous year [1]

Core Viewpoint - The company, Shuoshi Biotechnology (688399.SH), is expected to report a significant increase in losses for the fiscal year 2025, with projected net losses ranging from 29.4 million to 44 million yuan, compared to the previous year [1] Financial Performance - The estimated net profit attributable to the parent company for 2025 is projected to be between -29.4 million and -44 million yuan, representing an increase in losses by 27.4 million to 41.9 million yuan compared to the previous year [1] - The expected net profit attributable to the parent company, excluding non-recurring gains and losses, is forecasted to be between -81.9 million and -122.8 million yuan, indicating an increase in losses by 10.1 million to 50.9 million yuan compared to the previous year [1] Business Operations - The company's main business has shown stable development; however, it has faced challenges due to intensified industry competition and ongoing medical procurement reforms, leading to a decrease in revenue from self-produced diagnostic reagents [1] - The value-added tax rate for self-produced diagnostic reagents has been adjusted to 13%, contributing to the decline in revenue [1] - The company is actively implementing cost reduction and efficiency enhancement measures, aiming to maintain a stable overall gross profit margin compared to the previous year [1] Accounts Receivable Management - The company has intensified efforts to collect accounts receivable, resulting in a gradual decrease in the balance of long-aged accounts receivable [1] - There has been a reduction in the reversal of impairment provisions for receivables compared to the previous year [1]

Financial Performance - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between -29.4 million and -44 million yuan, representing an increase in losses of 27.4 million to 41.99 million yuan compared to the previous year [3]. - The expected net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -81.9 million and -122.8 million yuan, indicating an increase in losses of 10.06 million to 50.96 million yuan compared to the previous year [6]. - In 2024, the company reported a total profit of 4.1872 million yuan, with a net profit attributable to shareholders of the parent company of -0.2 million yuan [7]. Business Operations - The company has maintained stable development in its main business, but revenue from self-produced diagnostic reagents has declined due to intensified industry competition and ongoing medical procurement [8]. - The company has reduced the balance of long-aged accounts receivable through increased collection efforts, leading to a decrease in impairment provisions compared to the previous year [8]. Research and Development - The company has focused on R&D investments, maintaining a relatively high intensity of R&D spending despite a year-on-year decrease, and is enhancing its core product line and overall solution capabilities [10]. Government Support - The company has experienced a reduction in government subsidies received during the reporting period [10]. Earnings Forecast - The company has not identified any significant uncertainties that would affect the accuracy of this earnings forecast [11]. - The forecast data is preliminary and the final audited financial data will be disclosed in the 2025 annual report [12].

Core Viewpoint - The recent outbreak of Nipah virus in India has raised public concern, but experts believe it is unlikely to spread on a large scale like COVID-19 [1] Group 1: Company Developments - Multiple companies, including Antu Biology, Shuoshi Biology, Jinhao Pharmaceutical, Kaipu Biology, Zhijiang Biology, Zhongke Shengyi, Weiboxin Biology, and Shengke Yuan Biology, have developed nucleic acid testing reagents for Nipah virus and are actively supporting testing efforts [1] - There is reported procurement demand in relevant regions, although there have been no significant changes domestically; some key ports have a demand for reagent reserves [1] Group 2: Industry Insights - Experts, including Professor Jin Dongyan from the University of Hong Kong, suggest that Nipah virus is not a new virus and has caused small outbreaks with single-digit cases almost every year for the past two decades [1] - The current situation is not significantly different from previous years, and the virus has a low incidence of asymptomatic infections, allowing for effective control through isolation [1]

Group 1 - The Nipah virus, classified as a high-priority pathogen by the World Health Organization, has recently caused a new outbreak in West Bengal, India, with a mortality rate ranging from 40% to 75% [1][5] - As of now, there are 5 confirmed cases in West Bengal, with nearly 100 individuals under home quarantine [1] - The outbreak has affected travel plans, with some Chinese tourists canceling trips to Southeast Asia, and health monitoring measures have been intensified at Phuket International Airport for incoming Indian tourists [1][5] Group 2 - Experts indicate that while the risk of the Nipah virus entering China exists, it is currently considered manageable [3][8] - Preventive measures are emphasized, including avoiding contact with bats and pigs, and ensuring food safety [9][8] - Domestic companies have developed testing kits to assist in monitoring and controlling the outbreak, with firms like Shuoshi Biological and Cap Bio providing nucleic acid testing solutions [10][11] Group 3 - The development of targeted drugs and vaccines for the Nipah virus is challenging due to the virus's high danger level and the need for advanced laboratory conditions for research [11] - The sporadic nature of Nipah virus outbreaks complicates the accumulation of clinical trial data necessary for vaccine and drug validation [11] - Potential treatments, such as Favipiravir, have shown some efficacy against the Nipah virus in animal studies and are included in China's treatment guidelines for RNA virus infections [11]

证券之星消息，1月27日医疗器械板块较上一交易日下跌0.68%，硕世生物领跌。当日上证指数报收于 4139.9，上涨0.18%。深证成指报收于14329.91，上涨0.09%。医疗器械板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300639 | 凯普生物 | 8.70 | 20.00% | 173.48万 | | 14.29 乙 | | 002030 | 达安基因 | 7.71 | 9.99% | 271.53万 | | 20.71亿 | | 002901 | 大博医疗 | 51.90 | 7.45% | 7.24万 | | 3.71亿 | | 688607 | 康众医疗 | 66.99 | 6.91% | 5.11万 | | 3.30亿 | | 300289 | 利德曼 | 8.10 | 5.19% | 49.26万 | | 3.84亿 | | 688613 | 奥精医疗 | 24.51 | 5.19% | 7.92万 | | 2688T | | 68 ...

Core Viewpoint - The article highlights the outbreak of Nipah virus in West Bengal, India, and emphasizes the critical role of rapid and accurate testing in epidemic prevention and monitoring, given the virus's high mortality rate of 40%-75% and the absence of effective vaccines or treatments [3]. Group 1: Industry Response - Companies such as Capbio, Shuoshi Bio, and Zhongke Shengyi have quickly responded to the Nipah virus outbreak by providing testing kits to aid in epidemic monitoring and prevention [4]. - The Nipah virus is classified as a newly emerging zoonotic virus, causing severe diseases characterized by encephalitis or respiratory illnesses in infected individuals [6]. Group 2: Product Offerings - Capbio offers a range of Nipah virus nucleic acid testing kits using fluorescence PCR methods, with various packaging options available [11]. - The testing kits include specifications for different sample types such as serum, plasma, throat swabs, whole blood, urine, and viral cultures, with a detection limit of 500 copies/mL and a report time of 70 minutes [18].

Group 1 - The Nipah virus, classified as a high-priority pathogen by the World Health Organization, has recently caused a new outbreak in eastern India, with a mortality rate ranging from 40% to 75% [1][4] - As of now, West Bengal, India, has reported 5 confirmed cases, with nearly 100 individuals under home quarantine [1][4] - Initial investigations suggest that the first patient, a nurse, may have contracted the virus from contaminated fresh date palm juice [1][4] Group 2 - The outbreak has affected travel plans, with some Chinese tourists canceling trips to Southeast Asia due to concerns over the Nipah virus [3][6] - Health monitoring measures have been intensified at Phuket International Airport for Indian tourists, reflecting the potential impact on tourism [3][4] - Experts indicate that while the risk of the Nipah virus entering China exists, it is currently considered manageable [7][10] Group 3 - Several companies in China have developed domestic testing kits for the Nipah virus, which can assist in monitoring and controlling the outbreak [11] - Companies like Shuoshi Biological and Cap Bio have introduced nucleic acid testing kits to support public health efforts [11] - The development of targeted drugs and vaccines for the Nipah virus is challenging due to the virus's high danger level and the lack of sufficient clinical trial cases [12]